Table 2.
Groups | CFSE positive cells (%) | |||
---|---|---|---|---|
Thymus | Spleen | Injected BM | Non-injected BM | |
IB-eBMCs (n=6) | 1.98±0.44 | 3.34±0.63 | 9.93±1.36 | 7.2±1.48 |
IB-cBMCs (n=6) | 2.05±0.33 | 1.06±0.28* | 5.30±1.05* | 4.9±0.47# |
IV-eBMCs (n=6) | 1.81±0.42 | 2.35±0.39* | 4.94±1.08*,# | |
IV-cBMCs (n=6) | 1.66±0.18 | 2.17±0.52* | 4.13±0.85*,# |
Donor HSCs were isolated and labeled with CFSE. Suspended CFSE-labeled HSCs and unlabeled total BMCs were injected into the unirradiated recipient mice of different groups as described in Materials and Methods. 24 hours after HSCT, all animals were sacrificed to harvest cells from thymus, spleen and BMs for flow cytometry analysis. For IBBMT groups, BMs were distinguished as injected BM or non-injected BM. The results were expressed as the Mean ± SD (%) of 6 mice.
Represented p value for CFSE positive cells (%) in locations other than non-injected BM (Thymus, Spleen, Injected BM) of IB – eBMCs group versus each control group (IB – cBMCs, IV – eBMCs, IV – cBMCs group).
Represented p value for CFSE positive cells (%) in non-injected BM of IB-eBMCs versus each control group;
, p<0.05.